Candel Therapeutics (CADL) Competitors $9.10 +0.30 (+3.41%) (As of 11:51 AM ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends CADL vs. ARDX, SPRY, RCKT, BCAX, BCYC, AVDL, ZYME, AVXL, COLL, and PSTXShould you be buying Candel Therapeutics stock or one of its competitors? The main competitors of Candel Therapeutics include Ardelyx (ARDX), ARS Pharmaceuticals (SPRY), Rocket Pharmaceuticals (RCKT), Bicara Therapeutics (BCAX), Bicycle Therapeutics (BCYC), Avadel Pharmaceuticals (AVDL), Zymeworks (ZYME), Anavex Life Sciences (AVXL), Collegium Pharmaceutical (COLL), and Poseida Therapeutics (PSTX). These companies are all part of the "pharmaceutical products" industry. Candel Therapeutics vs. Ardelyx ARS Pharmaceuticals Rocket Pharmaceuticals Bicara Therapeutics Bicycle Therapeutics Avadel Pharmaceuticals Zymeworks Anavex Life Sciences Collegium Pharmaceutical Poseida Therapeutics Candel Therapeutics (NASDAQ:CADL) and Ardelyx (NASDAQ:ARDX) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their risk, institutional ownership, analyst recommendations, media sentiment, earnings, community ranking, profitability, valuation and dividends. Do insiders & institutionals believe in CADL or ARDX? 13.9% of Candel Therapeutics shares are owned by institutional investors. Comparatively, 58.9% of Ardelyx shares are owned by institutional investors. 41.6% of Candel Therapeutics shares are owned by insiders. Comparatively, 5.9% of Ardelyx shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term. Which has stronger earnings & valuation, CADL or ARDX? Candel Therapeutics has higher earnings, but lower revenue than Ardelyx. Ardelyx is trading at a lower price-to-earnings ratio than Candel Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioCandel Therapeutics$120K2,460.06-$37.94M-$1.73-5.25Ardelyx$251.85M4.45-$66.07M-$0.30-15.77 Is CADL or ARDX more profitable? Candel Therapeutics has a net margin of 0.00% compared to Ardelyx's net margin of -28.82%. Ardelyx's return on equity of -46.60% beat Candel Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Candel TherapeuticsN/A -629.29% -173.39% Ardelyx -28.82%-46.60%-21.49% Do analysts recommend CADL or ARDX? Candel Therapeutics presently has a consensus target price of $19.00, suggesting a potential upside of 109.02%. Ardelyx has a consensus target price of $10.42, suggesting a potential upside of 120.23%. Given Ardelyx's higher possible upside, analysts clearly believe Ardelyx is more favorable than Candel Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Candel Therapeutics 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00Ardelyx 0 Sell rating(s) 2 Hold rating(s) 5 Buy rating(s) 1 Strong Buy rating(s) 2.88 Does the MarketBeat Community prefer CADL or ARDX? Ardelyx received 520 more outperform votes than Candel Therapeutics when rated by MarketBeat users. Likewise, 67.52% of users gave Ardelyx an outperform vote while only 55.56% of users gave Candel Therapeutics an outperform vote. CompanyUnderperformOutperformCandel TherapeuticsOutperform Votes1055.56% Underperform Votes844.44% ArdelyxOutperform Votes53067.52% Underperform Votes25532.48% Which has more risk and volatility, CADL or ARDX? Candel Therapeutics has a beta of -0.95, meaning that its share price is 195% less volatile than the S&P 500. Comparatively, Ardelyx has a beta of 0.83, meaning that its share price is 17% less volatile than the S&P 500. Does the media prefer CADL or ARDX? In the previous week, Candel Therapeutics had 1 more articles in the media than Ardelyx. MarketBeat recorded 9 mentions for Candel Therapeutics and 8 mentions for Ardelyx. Ardelyx's average media sentiment score of 0.88 beat Candel Therapeutics' score of 0.75 indicating that Ardelyx is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Candel Therapeutics 3 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Ardelyx 4 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive SummaryArdelyx beats Candel Therapeutics on 12 of the 19 factors compared between the two stocks. Ad Behind the MarketsWe recommended Palantir in 2021, now we’re recommending this...My research indicates there is only one investment that can meet AI's unprecedented demand for energy.Click to get the name and ticker symbol Get Candel Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for CADL and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart CADL vs. The Competition Export to ExcelMetricCandel TherapeuticsBiological Products IndustryMedical SectorNASDAQ ExchangeMarket Cap$295.21M$2.96B$5.23B$9.26BDividend YieldN/A1.91%5.12%4.28%P/E Ratio-5.2546.4987.8717.28Price / Sales2,460.06422.161,162.56123.53Price / CashN/A174.7643.3837.82Price / Book20.664.004.864.99Net Income-$37.94M-$42.00M$120.72M$225.21M7 Day Performance-8.73%4.16%2.88%4.63%1 Month Performance96.75%-0.22%17.99%2.54%1 Year Performance697.37%16.79%29.13%17.21% Candel Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)CADLCandel Therapeutics2.8255 of 5 stars$9.10+3.4%$19.00+108.8%+685.7%$295.53M$120,000.00-5.2660Short Interest ↑ARDXArdelyx4.2346 of 5 stars$4.67-3.1%$10.42+123.1%-26.9%$1.11B$251.85M-15.57267Insider TradeSPRYARS Pharmaceuticals3.1736 of 5 stars$10.94-2.1%$24.00+119.4%+121.1%$1.06B$2.57M-21.4590RCKTRocket Pharmaceuticals4.6093 of 5 stars$11.41-1.3%$48.80+327.7%-61.2%$1.04BN/A-4.15240BCAXBicara TherapeuticsN/A$19.04+8.2%$43.00+125.8%N/A$1.04BN/A0.0032BCYCBicycle Therapeutics3.4973 of 5 stars$14.68flat$35.25+140.1%-21.3%$1.01B$36.90M-4.46240AVDLAvadel Pharmaceuticals2.7107 of 5 stars$10.16-1.5%$24.43+140.4%-25.9%$979.04M$138.16M-12.86154Positive NewsZYMEZymeworks2.8868 of 5 stars$14.05-0.6%$19.17+36.4%+43.8%$967.74M$62.20M-9.37290AVXLAnavex Life Sciences3.6163 of 5 stars$11.32+31.2%$43.00+279.9%+21.5%$959.89MN/A-22.6440Earnings ReportAnalyst ForecastShort Interest ↑News CoverageHigh Trading VolumeCOLLCollegium Pharmaceutical3.8647 of 5 stars$29.19-1.7%$42.60+45.9%-3.3%$941.38M$599.25M12.58210PSTXPoseida Therapeutics3.8817 of 5 stars$9.46+0.1%$9.50+0.4%+182.4%$924.94M$150.86M-15.02260Positive News Related Companies and Tools Related Companies ARDX Competitors SPRY Competitors RCKT Competitors BCAX Competitors BCYC Competitors AVDL Competitors ZYME Competitors AVXL Competitors COLL Competitors PSTX Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:CADL) was last updated on 12/26/2024 by MarketBeat.com Staff From Our Partnersliberals FOOLED by Elon’s shocking surpriseElon Musk and Donald Trump fooled everyone. They said it was to “save free speech”... Or “fix what the l...StocksToTrade | SponsoredThe Key to Feeding 8.1 Billion PeopleImagine a mineral so small it fits in the palm of your hand... yet its potential could transform the world's f...i2i Marketing Group, LLC | SponsoredWe recommended Palantir in 2021, now we’re recommending this...My research indicates there is only one investment that can meet AI's unprecedented demand for energy.Behind the Markets | SponsoredVladimir Lenin was right…The Magnificent 7 could be in for a world of pain… And the insiders know it. It’s why Jeff Bezos just sold ...Porter & Company | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowCrypto has officially entered the "banana zone" – that wild phase where prices can 1000x in days. It happen...Crypto Swap Profits | SponsoredDid You See Trump’s Bombshell Exec. Order 001?Starting with what I call Exec. Order 001. It’s a bombshell law that I believe Trump will sign within minut...Banyan Hill Publishing | SponsoredThis Crypto Is Set to Explode in DecemberIt's a groundbreaking opportunity that could be poised for extraordinary gains. The catalyst behind this su...Crypto 101 Media | Sponsored“AI Killer” 10x More Powerful Than ChatGPTElon Musk may be about to “kill” the world’s most powerful AI. Very few people are talking about the one AI...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Candel Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Candel Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
